Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Davunetide in Progressive Supranuclear Palsy
NCT01110720Phase 3Completed
- Sponsor
- Allon Therapeutics Inc.
- Start
- Oct 2010
- Primary completion
- Nov 2012
- Modality
- Peptides
- Countries
- 6
01
Overview
A Phase 3 trial of davunetide in progressive supranuclear palsy (PSP), sponsored by Allon Therapeutics Inc.. Started Oct 2010; status: completed.
02
Drugs
davunetide
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on NCT01110720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01110720.